Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0O1LD
|
|||
| Former ID |
DNC002374
|
|||
| Drug Name |
ZSTK474
|
|||
| Synonyms |
ZSTK474; 475110-96-4; ZSTK-474; 4,4'-(6-(2-(Difluoromethyl)-1H-benzo[d]imidazol-1-yl)-1,3,5-triazine-2,4-diyl)dimorpholine; ZSTK 474; TCMDC-137004; UNII-K0068GK39A; CHEMBL586702; CHEBI:90545; K0068GK39A; 2-(2-difluoromethylbenzimidazol-1-yl)-4,6-dimorpholino-1,3,5-triazine; 2-(2-Difluoromethylbenzimidazol-1-yl)-4,6-bis(morpholino)-1,3,5-triazine; AK-40326; 2-(Difluoromethyl)-1-(4,6-Dimorpholin-4-Yl-1,3,5-Triazin-2-Yl)-1h-Benzimidazole; C19H21F2N7O2; 2wxl; PubChem22461; SCHEMBL373282; QCR-72; GTPL7965; CTK8B6247; SYN1099
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Solid tumour/cancer [ICD-11: 2A00-2F9Z; ICD-10: C76-C80; ICD-9: 140-229] | Phase 1 | [1], [2] | |
| Therapeutic Class |
Anticancer Agents
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C19H21F2N7O2
|
|||
| Canonical SMILES |
C1COCCN1C2=NC(=NC(=N2)N3C4=CC=CC=C4N=C3C(F)F)N5CCOCC5
|
|||
| InChI |
1S/C19H21F2N7O2/c20-15(21)16-22-13-3-1-2-4-14(13)28(16)19-24-17(26-5-9-29-10-6-26)23-18(25-19)27-7-11-30-12-8-27/h1-4,15H,5-12H2
|
|||
| InChIKey |
HGVNLRPZOWWDKD-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 475110-96-4
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
16750771, 23750314, 26746633, 57376964, 77748024, 85756851, 85866113, 87225800, 99373532, 99436967, 103659086, 104149574, 109693182, 118049488, 123044197, 123051054, 123393012, 124756978, 125163783, 126579125, 126634934, 126666954, 126726470, 131480747, 134964393, 135684958, 135686132, 135686133, 135686154, 135686155, 135698920, 135727481, 136367276, 136367715, 137020279, 141089178, 143496971, 152234895, 152258832, 152344015, 160647683, 160820616, 161004407, 162011844, 162037416, 162202601, 163091161, 163379788, 163642384, 164043531
|
|||
| ChEBI ID |
CHEBI:90545
|
|||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7965). | |||
| REF 2 | Combination of the PI3K inhibitor ZSTK474 with a PSMA-targeted immunotoxin accelerates apoptosis and regression of prostate cancer. Neoplasia. 2013 Oct;15(10):1172-83. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.